A Prospective Evaluation of the Effect of Curcumin on Dose-limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Curcumin (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics
- 17 Mar 2017 Planned End Date changed from 1 Jun 2020 to 5 Oct 2018.
- 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2013 New trial record